Chondroblastoma

Chondroblastoma is a rare benign cartilage tumor accounting for less than 1% of all bone tumors. It is unique in arising from the epiphysis of long bones in skeletally immature patients (peak age 10-25 years). The characteristic histological feature is chicken-wire calcification - a lacy pattern of calcified lacunar rims surrounding chondroblasts. Despite being benign, chondroblastoma causes significant pain and can recur in 10-20% after curettage. Rare cases exhibit benign pulmonary metastasis (not malignant transformation) that may spontaneously regress.

The chicken-wire calcification pattern is created by calcification of the pericellular (lacunar) matrix around individual chondroblasts. On hematoxylin and eosin staining, this appears as a fine lacy network of purple-blue material outlining cells. At low magnification, it resembles chicken wire fencing. This pattern is PATHOGNOMONIC for chondroblastoma and distinguishes it from all other bone tumors including giant cell tumor.

Think chondroblastoma when:

• Adolescent (10-25 years) with chronic epiphyseal pain
• Pain worse with activity, not relieved with rest
• Joint effusion out of proportion to trauma history
• X-ray shows epiphyseal lytic lesion with sclerotic rim
• MRI shows bone marrow edema extending beyond lesion

Do NOT dismiss as growing pains or overuse injury - persistent epiphyseal pain in adolescent warrants imaging.

The classic teaching is "long-bone epiphysis," but a viva will test whether you know chondroblastoma also arises in epiphyseal-equivalent and atypical locations - and these behave or present differently.

• Apophyses (epiphyseal equivalents): the greater trochanter, tibial tubercle, iliac crest and patella - same biology as an epiphyseal lesion, because apophyses are secondary ossification centres. Keep chondroblastoma in the differential for a lytic apophyseal lesion in a young patient.
• Tarsal bones (talus and calcaneus): present late with vague hindfoot/ankle pain (often misdiagnosed as a sprain or a simple cyst), are technically difficult to access, and carry a higher recurrence rate than long-bone lesions.
• Craniofacial skeleton - classically the temporal bone/skull base: a recognised atypical site occurring in older patients than long-bone disease, presenting with hearing loss, temporomandibular symptoms or a skull-base mass.
• Flat and irregular bones (rib, pelvis, scapula) are rare but reported.

Exam point: chondroblastoma is not confined to the long-bone epiphysis - it also occurs in apophyses (greater trochanter, tibial tubercle, patella - epiphyseal equivalents), the tarsal bones (talus/calcaneus, which present late and recur more), and the craniofacial skeleton (temporal bone/skull base, in older patients) - so an epiphyseal-equivalent lytic lesion anywhere in a young patient should raise the diagnosis.

Both are epiphyseal lesions with giant cells, but key differences:

The MCQ section mentions radiofrequency ablation in passing, but it is worth knowing as a developing alternative to open curettage - increasingly used for the small, surgically difficult chondroblastoma.

• What and where: CT-guided percutaneous radiofrequency ablation (RFA) (or cryoablation) of a small lesion (typically under about 2 cm) in a deep or technically awkward site - classically the talus or the femoral head/neck - where open curettage is morbid.
• Advantages: day-case, no bone graft, bone-preserving, faster recovery.
• Critical caveats:
  • It provides no tissue diagnosis - a confirmatory biopsy must be obtained first (ideally at the same sitting); never ablate an undiagnosed epiphyseal lesion.
  • Thermal injury risk to adjacent articular cartilage (chondrolysis), an open physis (growth arrest), and neurovascular structures/skin within about 1 cm - so it is avoided for subarticular lesions hugging the joint surface or lesions close to nerves unless thermoprotection (hydrodissection, gas/saline insulation) is used.
  • Not suitable for larger lesions or those with a significant secondary ABC component; incomplete ablation/recurrence may require repeat ablation or conversion to curettage.

Exam point: percutaneous RFA/cryoablation is a minimally invasive option for the small chondroblastoma in a difficult site (talus, femoral head) - but it requires a diagnostic biopsy first and is limited by thermal risk to cartilage, physis and nerves, so it does not replace extended curettage for most accessible lesions.

Recurrence after curettage occurs in 10-20% despite adjuvants. Typical timeline: 1-3 years post-op. Management:

1. Confirm recurrence with MRI and biopsy (distinguish from bone graft resorption)
2. First recurrence: Repeat extended curettage with adjuvants - success rate 70-80%
3. Second recurrence: Consider wide excision if feasible (expendable bone)
4. Multiple recurrences: En bloc resection or accept disease and manage symptoms

Key point: Multiple recurrences do NOT indicate malignant transformation. Chondroblastoma is benign but can be locally persistent. Avoid radiation therapy due to malignant transformation risk.

Chondroblastoma is too rare for a dedicated implant registry; the evidence base is built from multicentre tumour-unit cohorts rather than arthroplasty-style registries. The recurring registry-grade message is that biopsy and definitive surgery should occur within a specialist musculoskeletal tumour unit, because an inappropriately placed biopsy tract can compromise later limb-salvage surgery. Reported local recurrence ranges widely by case-mix - approximately 5% in a mixed-maturity extremity cohort (Xu 2015) up to 32% in strictly open-physis paediatric lesions (Sailhan 2009) - reflecting that open-physis, strictly epiphyseal and proximal humeral/femoral lesions are the highest-risk groups.